Lunai Bioworks (LNAI) risk factors
Item 1A of every Lunai Bioworks Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2026 10-K risk factors56 risks3 new7 dropped21 reworded
Nasdaq compliance is a prominent new risk: stockholders’ deficit was $9.0 million versus Nasdaq’s $2.5 million equity requirement.
Filed Oct 13, 2026 - FY2025 10-K risk factors59 risks2 new1 dropped21 reworded
Expansion of risk disclosures to jointly cover BioSymetrics alongside Renovaro Cube following integration.
Filed Sep 29, 2025 - FY2024 10-K risk factors58 risks
This pre-clinical biotech and AI healthcare company faces severe going concern doubts with only $220,467 in cash as of June 30, 2024, and an accumulated deficit of $325 million. The risk profile is dominated by the heavy capital requirements for unproven gene, cell, and immunotherapy candidates and AI diagnostics. Reputation and business operations have been harmed by the arrest and indictment of co-founder Serhat Gümrükcü.
Filed Oct 10, 2024